Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioStem Technologies, Inc.BSEM · Entity 7054 | Director · Chief Executive Officer · 10% owner | October 07, 2026 | October 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioStem Technologies, Inc.
Report date October 07, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,553,551 |
Reported balance
After 2026-10-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-07 · Exercise / conversion · Acquired 250,000 · Balance 1,553,551 F1: The amount corrects the number of shares of common stock held by the Reporting Person, which over-reported a prior vesting of restricted stock units by one share in the Form 3 filed on August 14, 2026 and the Form 4 filed on September 17, 2026 due to an administrative error. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.00 · Expires 2032-10-24 | Direct | 2,000,000 |
Reported balance
After 2026-10-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-07 · Exercise / conversion · Disposed 250,000 · Balance 2,000,000 F5: These options are fully vested and exercisable. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2035-03-17 | Direct | 198,807 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 198,807 F6: These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2035-10-13 | Direct | 40,427 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 40,427 F7: These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2036-02-11 | Direct | 440,529 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 440,529 F8: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period. |
| Series A-1 Convertible Preferred SharesSEC Table II · derivative / convertible security | Direct | 100 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 100 F2: The Series A-1 Convertible Preferred Shares is convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares. F3: The Series A-1 Convertible Preferred Shares have no expiration date. F4: Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 33,874 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 33,874 F9: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F10: These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 99,901 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 99,901 F9: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F11: These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. F1: The amount corrects the number of shares of common stock held by the Reporting Person, which over-reported a prior vesting of restricted stock units by one share in the Form 3 filed on August 14, 2026 and the Form 4 filed on September 17, 2026 due to an administrative error. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 363,636 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 363,636 F9: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F12: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. |
Filing footnotes · ownership attribution and instrument terms
F1: The amount corrects the number of shares of common stock held by the Reporting Person, which over-reported a prior vesting of restricted stock units by one share in the Form 3 filed on August 14, 2026 and the Form 4 filed on September 17, 2026 due to an administrative error.
F2: The Series A-1 Convertible Preferred Shares is convertible in whole into shares of the Issuer's Common Stock on a one-to-one basis at the option of a majority of the holders of Series A-1 Convertible Preferred Shares.
F3: The Series A-1 Convertible Preferred Shares have no expiration date.
F4: Due to an administrative error, the Series A-1 Convertible Preferred Shares were inadvertently omitted from the Reporting Person's Form 3 filed on August 14, 2026.
F5: These options are fully vested and exercisable.
F6: These options vest according to the following schedule: 33% vested on March 17, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F7: These options vest according to the following schedule: 33% will vest on October 13, 2026, the one-year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F8: These options vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining options vesting in equal quarterly installments over the subsequent two year period.
F9: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F10: These restricted stock units vest in equal quarterly installments over three year from the grant date (September 15, 2024).
F11: These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
F12: These restricted stock units vest according to the following schedule: 33% will vest on February 11, 2027, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 9, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionOptions (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001193125-26-419152 · ownership.xml · derivative · entry 3 Matuszewski Jason · CIK 0001634730 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,000,000 Underlying: Common Stock · 250,000 shares Expires 2032-10-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| October 07, 2026 Filed Oct 9, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 250,000 | $2.00 | $500,000.00 |
DisclosureSEC source: 0001193125-26-419152 · ownership.xml · nonDerivative · entry 1 Matuszewski Jason · CIK 0001634730 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,553,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The amount corrects the number of shares of common stock held by the Reporting Person, which over-reported a prior vesting of restricted stock units by one share in the Form 3 filed on August 14, 2026 and the Form 4 filed on September 17, 2026 due to an administrative error. Read SEC document |
| September 17, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 16,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394398 · ownership.xml · derivative · entry 8 Matuszewski Jason · CIK 0001634730 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,900 Underlying: Common Stock · 16,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F7 · derivative.exercise_date: These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. F7 · derivative.expiration_date: These restricted stock units vest according to the following schedule: 33% vested on March 17, 2026, the one year anniversary of the grant date, with the remaining units vesting in equal quarterly installments over the subsequent two year period. Read SEC document |
| September 17, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 16,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394398 · ownership.xml · nonDerivative · entry 2 Matuszewski Jason · CIK 0001634730 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,303,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionRestricted Stock Units · Derivative | 8,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394398 · ownership.xml · derivative · entry 7 Matuszewski Jason · CIK 0001634730 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,874 Underlying: Common Stock · 8,469 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F6 · derivative.exercise_date: These restricted stock units vest quarterly over three years from the grant date (September 15, 2024). F6 · derivative.expiration_date: These restricted stock units vest quarterly over three years from the grant date (September 15, 2024). Read SEC document |
| September 15, 2026 Filed Sep 17, 2026 20:30 UTC | BioStem Technologies, Inc. BSEM · Entity 7054 | Exercise / conversionCommon Stock | 8,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-394398 · ownership.xml · nonDerivative · entry 1 Matuszewski Jason · CIK 0001634730 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,286,902 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.